Article
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS).
Cancer communications (London, England) - 1 Sept 2024
Lu Shun, Dong Xiaorong, Jian Hong, Chen Jianhua, Chen Gongyan, Sun Yuping, Ji Yinghua, Wang Ziping, Shi Jianhua, Lu Junguo, Chen Shaoshui, Lv Dongqing, Zhang Guojun, Liu Chunling, Li Juan, Yu Xinmin, Lin Zhong, Yu Zhuang, Wang Zhehai, Cui Jiuwei, Xu Xingxiang, Fang Jian, Feng Jifeng, Xu Zhi, Ma Rui, Hu Jie, Yang Nong, Zhou Xiangdong, Wu Xiaohong, Hu Chengping, Zhang Zhihong, Lu You, Hu Yanping, Jiang Liyan, Wang Qiming, Guo Renhua, Zhou Jianying, Li Baolan, Hu Chunhong, Tong Wancheng, Zhang Helong, Ma Lin, Chen Yuan, Jie Zhijun, Yao Yu, Zhang Longzhen, Weng Jie, Li Weidong, Xiong Jianping, Ye Xianwei, Duan Jianchun, Yang Haihua, Sun Meili, Wei Hongying, Wei Jiawei, Zhang Zheyu, Wu Qiong
Abstract excerpt
BACKGROUND: The initial randomized, double-blinded, actively controlled, phase III ANEAS study (NCT03849768) demonstrated that aumolertinib showed superior efficacy relative to gefitinib as first-line therapy in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC). Metastatic disease in the central nervous system (CNS) remains a challenge in the management of NSCLC. This...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.